Zogenix soars on 2015 hopes for abuse-deterrent Zohydro
This article was originally published in Scrip
Zogenix investors drove shares up 20% on 2 July after the company expressed confidence it would be ready to submit an application to the FDA by October for a harder-to-abuse version of the firm's controversial single-entity extended-release hydrocodone Zohydro ER – with the potential the new capsule formulation could be on the US market by early 2015.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.